
Sign up to save your podcasts
Or


On September 24, 2025, Hoth Therapeutics (NASDAQ: HOTH) announced the expansion of its intellectual property portfolio for HT-001, a topical therapeutic for chemotherapy-induced rash.
CEO Robb Knie discusses the development and potential of HT-001, along with other updates, including the oncology drug HT-KIT, our obesity initiative in partnership with the U.S. Department of Veterans Affairs, and more.
Learn more about the company: https://hoththerapeutics.com/
Watch the full YouTube interview here: https://youtu.be/99FydlxXwa8?si=uEm_KLqaggTfQSI8
And follow us to stay updated: https://www.youtube.com/@GlobalOneMedia?sub_confirmation=1
By Global One Media Pte. Ltd.5
2222 ratings
On September 24, 2025, Hoth Therapeutics (NASDAQ: HOTH) announced the expansion of its intellectual property portfolio for HT-001, a topical therapeutic for chemotherapy-induced rash.
CEO Robb Knie discusses the development and potential of HT-001, along with other updates, including the oncology drug HT-KIT, our obesity initiative in partnership with the U.S. Department of Veterans Affairs, and more.
Learn more about the company: https://hoththerapeutics.com/
Watch the full YouTube interview here: https://youtu.be/99FydlxXwa8?si=uEm_KLqaggTfQSI8
And follow us to stay updated: https://www.youtube.com/@GlobalOneMedia?sub_confirmation=1

229,965 Listeners

3,227 Listeners

1,364 Listeners

3,381 Listeners

945 Listeners

354 Listeners

148 Listeners

127 Listeners

21,233 Listeners

8,851 Listeners

1,040 Listeners

1,315 Listeners

16 Listeners

29,346 Listeners

52 Listeners